Células T CAR: Car T cells: Progress that passes the advances in the treatment of malignant hemopathies

Lina María Martínez-Sánchez; Luis Felipe Álvarez-Hernández; Mariana Roldán-Isaza

Células T CAR: Car T cells: Progress that passes the advances in the treatment of malignant hemopathies

Título traducido de la contribución: Células T CAR: Proeza que traspasa los avances en el tratamiento de las hemopatías malignas: Progress that passes the advances in the treatment of malignant hemopathies

Lina María Martínez-Sánchez, Luis Felipe Álvarez-Hernández, Mariana Roldán-Isaza

Salud Clínica y Quirúrgica

Producción científica: Contribución a una revista › Artículo de revisión › revisión exhaustiva

Resumen

Introduction: CAR T cells (antigenic chimeric receptor) are a new type of emergent treatment classified among adoptive cell transfer immunotherapies (ACT). This receptor will contribute to the detection of specific malignant antigens on the membrane of cancer cells and the destruction of these, which together with chemotherapy, allow an effective anti-tumor treatment.

Objective: to review the new therapies with CAR T cells in the common lymphomas, besides exposing the main complications and new therapeutic uses .

Methods: an exhaustive bibliographic review was carried out from December 2018 to June 2018 in databases such as Medline, Science Direct, Lilacs and Embase, with the search MeSH terms: lymphoma, immunotherapy, genetic engineering, T lymphocytes.

Conclusion: there are numerous applications of which this type of immunotherapy is a participant, currently proposes a therapeutic revolution in which not only include hematological malignancies, but also in solid tumors, is undoubtedly a feat of genetic engineering and medicine

Título traducido de la contribución	Células T CAR: Proeza que traspasa los avances en el tratamiento de las hemopatías malignas: Progress that passes the advances in the treatment of malignant hemopathies
Idioma original	Español
Páginas (desde-hasta)	41-50
Número de páginas	10
Publicación	Revista Cubana de Hematologia, Inmunologia y Hemoterapia
Volumen	34
N.º	4
Estado	Publicada - 1 oct. 2018

Nota bibliográfica

Publisher Copyright:
© 2018, Editorial Ciencias Medicas. All rights reserved.

Palabras clave

CAR T
Genetic engineering
Immunotherapy
Lymphoma
T-lymphocytes

Tipos de Productos Minciencias

Artículos de investigación con calidad Q4

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Citar esto

@article{f73bf0a692544394a4e401e7afb1380b,

title = "C{\'e}lulas T CAR: Car T cells: Progress that passes the advances in the treatment of malignant hemopathies",

abstract = "Introduction: CAR T cells (antigenic chimeric receptor) are a new type of emergent treatment classified among adoptive cell transfer immunotherapies (ACT). This receptor will contribute to the detection of specific malignant antigens on the membrane of cancer cells and the destruction of these, which together with chemotherapy, allow an effective anti-tumor treatment. Objective: to review the new therapies with CAR T cells in the common lymphomas, besides exposing the main complications and new therapeutic uses . Methods: an exhaustive bibliographic review was carried out from December 2018 to June 2018 in databases such as Medline, Science Direct, Lilacs and Embase, with the search MeSH terms: lymphoma, immunotherapy, genetic engineering, T lymphocytes. Conclusion: there are numerous applications of which this type of immunotherapy is a participant, currently proposes a therapeutic revolution in which not only include hematological malignancies, but also in solid tumors, is undoubtedly a feat of genetic engineering and medicine",

keywords = "CAR T, Genetic engineering, Immunotherapy, Lymphoma, T-lymphocytes",

author = "Mart{\'i}nez-S{\'a}nchez, {Lina Mar{\'i}a} and {\'A}lvarez-Hern{\'a}ndez, {Luis Felipe} and Mariana Rold{\'a}n-Isaza",

year = "2018",

month = oct,

day = "1",

language = "Espa{\~n}ol",

volume = "34",

pages = "41--50",

journal = "Revista Cubana de Hematologia, Inmunologia y Hemoterapia",

issn = "0864-0289",

publisher = "Editorial Ciencias Medicas",

number = "4",

}

Células T CAR: Car T cells: Progress that passes the advances in the treatment of malignant hemopathies. / Martínez-Sánchez, Lina María; Álvarez-Hernández, Luis Felipe; Roldán-Isaza, Mariana.
En: Revista Cubana de Hematologia, Inmunologia y Hemoterapia, Vol. 34, N.º 4, 01.10.2018, p. 41-50.

Producción científica: Contribución a una revista › Artículo de revisión › revisión exhaustiva

TY - JOUR

T1 - Células T CAR

T2 - Car T cells: Progress that passes the advances in the treatment of malignant hemopathies

AU - Martínez-Sánchez, Lina María

AU - Álvarez-Hernández, Luis Felipe

AU - Roldán-Isaza, Mariana

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Introduction: CAR T cells (antigenic chimeric receptor) are a new type of emergent treatment classified among adoptive cell transfer immunotherapies (ACT). This receptor will contribute to the detection of specific malignant antigens on the membrane of cancer cells and the destruction of these, which together with chemotherapy, allow an effective anti-tumor treatment. Objective: to review the new therapies with CAR T cells in the common lymphomas, besides exposing the main complications and new therapeutic uses . Methods: an exhaustive bibliographic review was carried out from December 2018 to June 2018 in databases such as Medline, Science Direct, Lilacs and Embase, with the search MeSH terms: lymphoma, immunotherapy, genetic engineering, T lymphocytes. Conclusion: there are numerous applications of which this type of immunotherapy is a participant, currently proposes a therapeutic revolution in which not only include hematological malignancies, but also in solid tumors, is undoubtedly a feat of genetic engineering and medicine

AB - Introduction: CAR T cells (antigenic chimeric receptor) are a new type of emergent treatment classified among adoptive cell transfer immunotherapies (ACT). This receptor will contribute to the detection of specific malignant antigens on the membrane of cancer cells and the destruction of these, which together with chemotherapy, allow an effective anti-tumor treatment. Objective: to review the new therapies with CAR T cells in the common lymphomas, besides exposing the main complications and new therapeutic uses . Methods: an exhaustive bibliographic review was carried out from December 2018 to June 2018 in databases such as Medline, Science Direct, Lilacs and Embase, with the search MeSH terms: lymphoma, immunotherapy, genetic engineering, T lymphocytes. Conclusion: there are numerous applications of which this type of immunotherapy is a participant, currently proposes a therapeutic revolution in which not only include hematological malignancies, but also in solid tumors, is undoubtedly a feat of genetic engineering and medicine

KW - CAR T

KW - Genetic engineering

KW - Immunotherapy

KW - Lymphoma

KW - T-lymphocytes

UR - https://www.scopus.com/record/display.uri?eid=2-s2.0-85067114533&origin=resultslist&sort=plf-f&src=s&sid=f4e4a97b56fb5881a21c31c40b9b9e0d&sot=b&sdt=b&s=TITLE-ABS-KEY%28C%C3%A9lulas+T+CAR%3A+proeza+que+traspasa+los+avances+en+el+tratamiento+de+las+hemopat%C3%ADas+malignas%29&sl=87&sessionSearchId=f4e4a97b56fb5881a21c31c40b9b9e0d

M3 - Artículo de revisión

AN - SCOPUS:85067114533

SN - 0864-0289

VL - 34

SP - 41

EP - 50

JO - Revista Cubana de Hematologia, Inmunologia y Hemoterapia

JF - Revista Cubana de Hematologia, Inmunologia y Hemoterapia

IS - 4

ER -

Células T CAR: Car T cells: Progress that passes the advances in the treatment of malignant hemopathies

Resumen

Nota bibliográfica

Palabras clave

Tipos de Productos Minciencias

ODS de las Naciones Unidas

Huella

Citar esto